Concert Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Concert Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-4,637	Closed	-$216K	–	883
2016 Q3	$216K	Buy	4,637 +111	+2%	+$5.79K	0.03%	616
2016 Q2	$229K	Sell	4,526 -2,312	-34%	-$123K	0.03%	557
2016 Q1	$364K	Buy	6,838 +141	+2%	+$8.27K	0.05%	419
2015 Q4	$439K	Sell	6,697 -3,797	-36%	-$235K	0.06%	386
2015 Q3	$591K	Buy	+10,494	New	+$680K	0.08%	316
2015 Q2	–	Sell	-3,830	Closed	-$205K	–	719
2015 Q1	$205K	Sell	3,830 -282	-7%	-$16.4K	0.06%	390
2014 Q4	$242K	Buy	+4,112	New	+$229K	0.04%	526
2013 Q3	–	Sell	-5,867	Closed	-$232K	–	541
2013 Q2	$232K	Buy	+5,867	New	+$228K	0.03%	412

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Concert Wealth Management's TEVA Position: Q4 2016 in Review

Concert Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 4,637 shares — an estimated $216K sold.

Concert Wealth Management first reported a position in TEVA in Q2 2013 and held it in 8 quarters. The position peaked at $591K in Q3 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Concert Wealth Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Concert Wealth Management sold 4,637 Teva Pharmaceuticals shares in Q4 2016, an estimated $216K.
Concert Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 8 quarters.
Concert Wealth Management's Teva Pharmaceuticals position peaked at $591K in Q3 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Concert Wealth Management's 13F filing for Q4 2016, filed 10 Feb 2017.